Development of model for identifying homologous recombination deficiency (HRD) status of ovarian cancer with deep learning on whole slide images

被引:0
|
作者
Zhang, Ke [1 ]
Qiu, Youhui [2 ]
Feng, Songwei [1 ]
Yin, Han [1 ]
Liu, Qi [1 ]
Zhu, Yuxin [1 ]
Cui, Haoyu [2 ]
Wei, Xiaoying [3 ]
Wang, Guoqing [3 ]
Wang, Xiangxue [2 ]
Shen, Yang [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Sch Med, Dept Obstet & Gynaecol, Nanjing 210009, Peoples R China
[2] Nanjing Univ Informat Sci & Technol, Inst AI Med, Sch Artificial Intelligence, Nanjing, Peoples R China
[3] Southeast Univ, Zhongda Hosp, Sch Med, Dept Pathol, Nanjing, Peoples R China
关键词
Deep learning; Whole slide images (WSIs); Homologous recombination deficiency (HRD); Ovarian cancer; FEATURES;
D O I
10.1186/s12967-025-06234-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
BackgroundHomologous recombination deficiency (HRD) refers to the dysfunction of homologous recombination repair (HRR) at the cellular level. The assessment of HRD status has the important significance for the formulation of treatment plans, efficacy evaluation, and prognosis prediction of patients with ovarian cancer.ObjectivesThis study aimed to construct a deep learning-based classifier for identifying tumor regions from whole slide images (WSIs) and stratify the HRD status of patients with ovarian cancer (OC).MethodsThe deep learning models were trained on 205 H&E-stained sections which contained 205 ovarian cancer patients, 64 were found to have HRD status while 141 had homologous recombination proficiency (HRP) status from two institutions Memorial Sloan Kettering Cancer Center (MSKCC) and Zhongda Hospital, Southeast University. The framework includes tumor regions identification by UNet + + and subtypes of ovarian cancer classifier construction. Referring to the EasyEnsemble, we classified the HRP patients into three distributed subsets. These three subsets of HRP patients were combined with the HRD patients to establish three new training groups for subsequent model construction. The three models were integrated into a single model named Ensemble Model.ResultsThe UNet + + algorithm segmented tumor regions with 81.8% accuracy, 85.9% recall, 83.8% dice score and 68.3% IoU. The AUC of the Ensemble Model was 0.769 (Precision = 0.800, Recall = 0.727, F1-score = 0.762) in the study. The most discriminative features between HRD and HRP comprised S_mean_dln_obtuse_ratio, S_mean_dln_acute_ratio and mean_Graph_T-S_Betweenness_normed.ConclusionsThe models we constructed enables accurate discrimination between tumor and non-tumor tissues in ovarian cancer as well as the prediction of HRD status for patients with ovarian cancer.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] In-House Testing for Homologous Recombination Deficiency (HRD) in Mexican Patients with High-Grade Serous Ovarian Cancer
    Abreu-Gonzalez, Melania
    Santillan-Martinez, Rosalia
    Garcia-Ortiz, Ramiro
    Alvarez Ordorica, Oliver
    Martinez-Cannon, Bertha A.
    Hernandez Luis, Gisela
    Tellez Bernal, Eduardo
    Cortes Esteban, Patricia
    Blanco Vazquez, Yazmin C.
    Lopez Rosas, Gilberto
    Gomez Garcia, Eva M.
    Sanchez Llamas, Benito
    Rojas Toledo, Emma X.
    Martinez Gutierrez, Selena
    Azotla Vilchis, Coztli O.
    Rodriguez Munoz, Yolanda F.
    Munoz, Alexia
    Montes-Servin, Edgar
    Mendoza-Maldonado, Lucero
    Vaisman, Carolina E.
    Juarez Rodriguez, Rocio
    Flores Palacios, Jose A.
    Lara Torres, Cesar O.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (06): : S53 - S54
  • [32] Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
    Incorvaia, Lorena
    Brando, Chiara
    Perez, Alessandro
    Bono, Marco
    Cancelliere, Daniela
    Pivetti, Alessia
    Barraco, Nadia
    Contino, Silvia
    Raso, Chiara Annamaria
    Carreca, Anna Paola
    Gristina, Valerio
    Galvano, Antonio
    Russo, Tancredi Didier Bazan
    Castellana, Luisa
    Insalaco, Lavinia
    Fanale, Daniele
    Marchetti, Claudia
    Bazan, Viviana
    Russo, Antonio
    Carreca, Ignazio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC)
    Patel, J.
    Sehouli, J.
    Timms, K.
    Solimeno, C.
    Reid, J.
    Lanchbury, J.
    Braicu, I.
    Darb-Esfahani, S.
    Ganapathi, M.
    Ganapathi, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [34] Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer
    Fountzilas, Elena
    Papadopoulou, Kyriaki
    Chatzikonstantinou, Thomas
    Karakatsoulis, Georgios
    Constantoulakis, Pantelis
    Tsantikidi, Aikaterini
    Tsaousis, Georgios
    Karageorgopoulou, Sofia
    Koumarianou, Anna
    Mauri, Davide
    Ntavatzikos, Anastasios
    Saridaki, Zacharenia
    Petrakis, Georgios
    Fostira, Florentia
    Fountzilas, George
    Liontos, Michalis
    CANCERS, 2023, 15 (23)
  • [35] DeepBatch: A hybrid deep learning model for interpretable diagnosis of breast cancer in whole-slide images
    Zeiser, Felipe Andre
    da Costa, Cristiano Andre
    Ramos, Gabriel de Oliveira
    Bohn, Henrique C.
    Santos, Ismael
    Roehe, Adriana Vial
    EXPERT SYSTEMS WITH APPLICATIONS, 2021, 185
  • [36] A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance.
    Buisson, Adrien
    Saintigny, Pierre
    Pujade-Lauraine, Eric
    Montoto-Grillot, Christine
    Vacirca, Davide
    Barberis, Massimo
    Colombo, Nicoletta
    Harle, Alexandre
    Gilson, Pauline
    Roma, Cristin
    Bergantino, Francesca
    Harter, Philipp
    Pignata, Sandro
    Martin, Antonio Gonzalez
    Schauer, Christian
    Fujiwara, Keiichi
    Vergote, Ignace
    Nottrup, Trine Jakobi
    Just, Pierre-Alexandre
    Ray-Coquard, Isabelle Laure
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17599 - E17599
  • [37] The correlation of homologous recombination deficiency status with and Olaparib efficacy in Chinese ovarian cancer patients.
    Peng, Yongpai
    Xie, Qingsheng
    Xu, Guocai
    Zhang, Bingzhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17556 - E17556
  • [38] Streamline of the gene line: Implementation of reflex homologous recombination deficiency (HRD) tumor testing in newly diagnosed ovarian cancer patients
    Byrne, Maureen
    Mckenna, Danielle
    Schumacher, Ryan
    Shah, Payal
    Mastroyannis, Spyridon Alexandros
    Lodise, Amy
    Oliver, Sirithepphavanh
    Schwartz, Lauren
    Martin, Lainie
    Domchek, Susan
    Haggerty, Ashley
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S287 - S288
  • [39] DEVELOPING A WHOLE EXOME SEQUENCING-BASED HOMOLOGOUS RECOMBINATION DEFICIENCY TEST OF EPITHELIAL OVARIAN CANCER
    Lin, Po-Han
    Kuo, Kuan-Ting
    Hwu, Wuh-Liang
    Huang, Hsien-Neng
    Lin, Tzu-Ying
    Chen, Chieh Min
    Chiang, Ying-Cheng
    Cheng, Wen-Fang
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A173 - A173
  • [40] A Deep Learning Model for Cervical Cancer Screening on Liquid-Based Cytology Specimens in Whole Slide Images
    Kanavati, Fahdi
    Hirose, Naoki
    Ishii, Takahiro
    Fukuda, Ayaka
    Ichihara, Shin
    Tsuneki, Masayuki
    CANCERS, 2022, 14 (05)